Mirati Therapeutics, Inc.
MRTX

$4.12 B
Marketcap
$58.70
Share price
Country
$-0.10
Change (1 day)
$64.41
Year High
$27.30
Year Low
Categories

Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; and Sitravatinib, an investigational spectrum-selective kinase inhibitor that is in Phase 3 clinical trial for the treatment of NSCL cancer, as well as a KRAS G12D inhibitor program, which is in preclinical development. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.

marketcap

P/S ratio for Mirati Therapeutics, Inc. (MRTX)

P/S ratio as of 2022: 204.88

According to Mirati Therapeutics, Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 204.88. At the end of 2021 the company had a P/S ratio of 105.57.

P/S ratio history for Mirati Therapeutics, Inc. from 2003 to 2022

P/S ratio at the end of each year

Year P/S ratio
2022 204.88
2021 105.57
2020 737.50
2019 1447.70
2018 101.40
2017 0.00
2016 0.00
2015 0.00
2014 0.00
2013 0.00
2012 34919.56
2011 14.80
2010 2.39
2009 1.83
2008 0.21
2007 0.32
2006 0.29
2005 0.53
2004 0.35
2003 0.30